脑出血后胃造瘘管置入预测:GRAVo评分的外部验证
本研究从已完成的多中心、随机、双盲无效性设计临床试验——脑出血去铁胺试验中选取患者,对前瞻性收集的数据进行回顾性分析,外部验证GRAVo评分对脑出血后经皮胃造瘘(PEG)管置入的预测价值。共291例数据完整的患者纳入分析,38例(13%)接受了PEG置管;PEG组与非PEG组的中位GRAVo评分分别为4分(四分位距3-4)与2分(四分位距2-3)(p < 0.0001)。GRAVo评分外部验证的AUROC为0.7008(95%CI 0.6036-0.78);去除种族变量后的模型AUROC为0.6958(95%CI 0.6124-0.7891),两条ROC曲线高度重叠。作者认为外部验证结果证实GRAVo评分对脑出血后PEG置管具有预测效度,但性能较推导队列有所下降,使用该评分辅助临床决策时需考虑队列间患者特征差异可能影响结果。
要点
- GRAVo评分由以下变量构成:格拉斯哥昏迷评分≤12分(2分)、种族(黑种人1分)、年龄>50岁(2分)、脑出血体积>30 mL(1分)。
- 外部验证队列291例中38例(13%)接受PEG置管,PEG组中位GRAVo评分4分(四分位距3-4)vs 非PEG组2分(四分位距2-3),p < 0.0001。
- GRAVo评分预测PEG置管的AUROC为0.7008(95%CI 0.6036-0.78),去除种族变量后AUROC为0.6958(95%CI 0.6124-0.7891)。
- 作者指出GRAVo评分外部验证性能较推导队列有所下降,使用该评分辅助PEG置管临床决策时需考虑队列间患者特征差异的影响。
适用人群与场景
- 选自脑出血去铁胺试验(多中心、随机、双盲无效性设计临床试验)的脑出血患者,对前瞻性收集数据进行回顾性分析,共291例数据完整者纳入分析。
诊断标准与关键阈值
- GRAVo评分计算(采用既往建立的方法):格拉斯哥昏迷评分≤12分计2分,种族为黑种人计1分,年龄>50岁计2分,脑出血体积>30 mL计1分。
研究设计与关键结果
- 研究类型:对多中心、随机、双盲无效性设计临床试验(脑出血去铁胺试验)前瞻性收集数据的回顾性分析;样本量291例,其中38例(13%)接受PEG置管。
- PEG组中位GRAVo评分为4分(四分位距3-4),非PEG组为2分(四分位距2-3),p < 0.0001。
- 在校正去铁胺暴露后,采用logistic回归分析GRAVo评分与PEG置管的关联;GRAVo评分外部验证的AUROC为0.7008(95%CI 0.6036-0.78)。
- 去除种族变量后的模型AUROC为0.6958(95%CI 0.6124-0.7891),两模型ROC曲线高度重叠。
证据类型、等级与局限
- 证据类型:对多中心随机双盲无效性设计临床试验数据的外部验证分析(回顾性分析前瞻性收集数据)。
- 局限:作者指出GRAVo评分外部验证性能较推导队列有所下降;队列间患者特征差异可能影响结果;使用该评分辅助PEG置管临床决策时需考虑这些发现。
对床旁实践的改变
- 作者认为外部验证结果证实GRAVo评分对脑出血后PEG置管具有预测效度,但性能较推导队列有所下降;使用该评分辅助PEG置管临床决策时需考虑队列间患者特征差异可能影响结果。
- 作者报告加入种族变量对模型性能无 measurable 影响(AUROC 0.7008 vs 0.6958,ROC曲线高度重叠)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dysphagia is a common consequence of intracerebral hemorrhages (ICH). It can lead to enduring impairments of dietary intake and the requirement for feeding via percutaneous gastrostomy (PEG) tubes. However, variabilities in the course of swallowing recovery after ICH make it difficult to anticipate the need for PEG placement in an individual patient. A new tool called the GRAVo score was recently developed to predict PEG tube placement after an ICH but has not been externally validated. Our study aims were to externally validate the GRAVo score in a multicenter cohort and reexamine the role of race in predicting PEG placement, given the uncertain biological plausibility for this relationship observed in the derivation cohort.
METHODS: Patients for this analysis were selected from a previously completed multicenter, randomized, double-blind futility design clinical trial, the Intracerebral Hemorrhage Deferoxamine trial, and underwent a retrospective review of prospectively collected data. The GRAVo scores were computed by using previously established methods using the following variables: Glasgow Coma Scale ≤ 12 (2 points), race (1 point for Black), age > 50 years (2 points), and ICH volume > 30 mL (1 point). Association of GRAVo scores with PEG placement were examined by using logistic regression analysis after adjustment for exposure to deferoxamine. Model performance was estimated by using area under the receiving operating characteristic curve (AUROC). Subsequently, a second model was created by excluding scores for race, and the AUROC of both models were compared.
RESULTS: A total of 291 patients with complete data points served as the study cohort; 38 (13%) underwent PEG placement. The median GRAVo score for patients in the PEG and non-PEG groups were 4 (interquartile range 3-4) versus 2 (interquartile range 2-3), respectively (p < 0.0001). External validation of the GRAVo score yielded an AUROC of 0.7008 (95% confidence interval 0.6036-0.78); the model obtained without assignment of scores for the variable race yielded an AUROC of 0.6958 (95% confidence interval 0.6124-0.7891). The receiver operating characteristic curves from both models demonstrated close overlap.
CONCLUSIONS: The results of our external validation demonstrate the validity of GRAVo scores for predicting PEG tube placement after an ICH. However, its performance was more modest compared with that of the derivation cohort. Inclusion of the race variable had no measurable effect on model performance. Differences in patient characteristics between these cohorts may have influenced our results. These findings should be taken into consideration when using the GRAVo score to assist clinical decision making on PEG placement after an ICH.
参考来源
- Lin D, Minyetty M, Selim M, et al. Predicting Gastrostomy Tube Placement After Intracerebral Hemorrhage: External Validation of the GRAVo Score. Neurocrit Care. 2022. PMID: 35606561. doi:10.1007/s12028-022-01523-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。